| J9271 | Injection, pembrolizumab, 1 mg | 12,700 | $40 | $546.1K |
| J9299 | Injection, nivolumab, 1 mg | 16,640 | $20 | $399.4K |
| J0897 | Injection, denosumab, 1 mg | 7,740 | $20 | $147.1K |
| Q5107 | Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg | 5,180 | $20 | $119.1K |
| 99233 | The provider sees a patient for a subsequent hospital inpatient or observation care visit involving evaluation and management (E/M). The visit involves a high level of medical decision making or the… | 1,130 | $100 | $111.8K |
| J2506 | Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | 1,190 | $80 | $98.6K |
| 99215 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the… | 520 | $150 | $77.2K |
| 96413 | Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These… | 520 | $120 | $62.5K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 520 | $100 | $51.9K |
| 99223 | The provider sees a patient for an initial hospital inpatient or observation care visit involving evaluation and management (E/M). The visit involves a high level of medical decision making or the… | 250 | $140 | $35.6K |